Original source: eMedicine Medscape
Acquired Angioedema Due to C1 Inhibitor Deficiency
Acquired angioedema (AAE) due to acquired C1-inhibitor (C1-INH) deficiency (C1-INH-AAE) is a rare disorder caused by acquired consumption of C1-INH. It is clinically characterized by recurrent episodes of nonpitting asymmetric edema of the face, lips, tongue, limbs, and genitals; severe abdominal pain due to edema of the gastrointestinal mucosa; and life-threatening edema of the upper respiratory tract. It is not associated with urticaria and is not an immunoglobulin E (IgE)‒mediated process.
Acquired angioedema was first described by Caldwell et al in 1972. The three key elements that initially characterized acquired angioedema were acquired deficiency of C1-INH, hyperactivation of the classic pathway of human complement, and recurrent angioedema symptoms. [1]
Two distinct syndromes are described below. Both types of acquired angioedema (AAE) without urticaria are characterized by painless, nonpruritic, nonpitting swelling of the skin. They are classified into 2 forms: acquired angioedema type I (AAE-I) and acquired angioedema type II (AAE-II).
Acquired angioedema type I is associated with other diseases, most commonly B-cell lymphoproliferative disorders. Acquired angioedema type II is an autoimmune process defined by the presence of an autoantibody directed against the C1 inhibitor molecule (C1-INH).
Go to Angioedema, Pediatric Angioedema, Acute Angioedema, and Hereditary Angioedema for complete information on this topic.
C1-INH is a multifunctional serine protease inhibitor that is normally present in high concentrations in plasma. It is primarily synthesized by hepatocytes. Its synthesis is up-regulated by interferon-gamma, interleukin 6, and interleukin 1. Androgens may also have a role in stimulating C1-INH synthesis. The major functions of C1-INH include inhibition of activated C1r and C1s, inhibition of activated Hageman factor (XIIa), and inhibition of activated kallikrein, the contact system protease that cleaves kininogen and releases bradykinin. [2]
Bradykinin is an important mediator involved in tissue permeability and vascular dilatation. Its biological effect is exerted through activation of bradykinin B2 receptors, which are expressed in the membranes of endothelial and smooth muscles cells. Elevated blood bradykinin levels are found during clinical flares in patients with angioedema. Other kinins may also be pathogenic. [2]
The specific trigger responsible for inducing the release of these vasoactive peptides is unclear. Activation of factor XII (Hageman factor) may be secondary to phospholipid release from damaged or apoptotic cells and may be important in the generation of bradykinin from endothelial activation. This hypothesis encompasses the role of illness or tissue injury in the generation of bradykinin.
Supporting the importance of bradykinin in acquired angioedema, vascular permeability has been shown to increase in mice deficient in C1-INH, but not in mice with a deficiency in both C1-INH and the bradykinin B2 receptor. [3] The precise pathophysiology of acquired angioedema type I remains to be defined. C1-INH levels diminish as a result of its increased catabolism and excessive activation of the classic complement pathway.
Although the current classification of acquired angioedema is being readdressed, in acquired angioedema type I, the associated disorders (usually lymphoproliferative malignancies) produce complement-activating factors, idiotype/anti-idiotype antibodies, or other immune complexes that destroy C1-INH function. Neoplastic lymphatic tissue has been found to play an active role in the consumption of C1-INH and the complement components of the classic pathway.
The most commonly associated malignancy, B-cell lymphoma, has shown that anti-idiotypic antibody attached to immunoglobulin on the surface of B-cells causes C1-INH deficiency. Increased consumption of C1q followed by C2 and C4 results in subsequent release of vasoactive peptides that act on postcapillary venules.
In acquired angioedema type II, a normal 105-kd C1-INH molecule is synthesized in adequate amounts but, because of an unknown event, a subpopulation of B cells secretes autoantibodies to the C1-INH molecule. This autoantibody, which may be of any of the major immunoglobulin classes, binds to the reactive center of C1-INH. After binding to C1-INH and altering its structure, its regulatory capacity is diminished or abrogated.
In all reported cases of C1-INH deficiency caused by an autoantibody, C1-INH circulates in the blood in a form that has been cleaved by target proteases from its native molecule to a 95-kd fragment. Because of the higher affinity of the autoantibody for native C1-INH, the 95-kd antibody/C1-INH complex dissociates, and the freed antibody can bind to another native C1-INH molecule, further depleting C1-INH.
The distinction between acquired angioedema type I and acquired angioedema type II may be difficult to make at times, and it is imperative to stress that overlap does occur. For instance, cases of monoclonal gammopathy of undetermined significance (MGUS) have shown the monoclonal immunoglobulin itself to be the C1-INH antibody. Patients with acquired angioedema type I may initially present with autoantibodies to C1-INH, or the autoantibodies may develop as the disease progresses. While measuring antibodies against C1-INH is useful, groups have also developed assays that can measure the antibody against C1-INH in complex with C1-INH. In one study, anti–C1-INH antibodies were detected in 9 of 20 patients, while the complex between anti–C1-INH and C1-INH was found in 18 of 20, suggesting that there could be greater numbers of patients with anti–C1-INH antibodies than is seen when measuring antibody alone. [4]
Acquired angioedema type I is most frequently associated with B-cell lymphoproliferative disease. To date, only three reports of a T-cell lymphoma associated with acquired angioedema type I have been documented. [5]
Other associated disorders have included the following:
Essential cryoglobulinemia
Infection with Helicobacter pylori or Echinococcus granulosis
Acquired angioedema type II is not associated with any specific disorder but rather is characterized by the presence of autoantibody directed against C1-INH. Most of these antibodies work by binding the epitopes around the reactive center of INH. [6] However, the occasional existence of features of both acquired angioedema type I and acquired angioedema type-II has been noted, most notably with a MGUS.
A 2016 study reported that 33% of patients presenting with acquired angioedema had or would develop non-Hodgkin lymphoma, in particular marginal zone lymphoma. Of the studied patients, 62.5% were diagnosed with non-Hodgkin lymphoma at the onset of angioedema or up to 7 years later. Patients presenting with acquired angioedema and C1-INH deficiency should be monitored regularly for the development of malignancy. [7]
In addition to associations with MGUS, C1-INH–deficient AAE has also been reported in monoclonal gammopathy of renal significance (MGRS). [8] One case of acquired angioedema with C1-INH deficiency state was identified in association with liver transplantation. The status of the liver donor was unknown, but it is speculated that the donor may have been C1-INH deficient. Another case of acquired angioedema was reported with acute upper airway angioedema in association with the local anesthetic articaine.
Acquired angioedema is rare. Only approximately 150 cases have been reported in the medical literature worldwide.
Persons of any race can be affected by acquired angioedema. Men and women are equally affected.
The onset of acquired angioedema is most common after the fourth decade of life, whereas the usual onset of hereditary acquired angioedema (HAE) is in the second decade.
The prognosis for patients with acquired angioedema is variable, and, in most cases, it depends on control of the underlying disorder. However, even with appropriate treatment of the underlying disease, patients may be free of symptoms only temporarily. Additionally, some patients who have had their underlying disease treated will be free of symptoms related to angioedema but will continue to have biochemical abnormalities. [9]
Compared with the general population, patients with acquired angioedema have a higher incidence of B-cell malignancies. Patients with acquired angioedema and a concurrent diagnosis of monoclonal gammopathy of undetermined significance (MGUS) do not have an increased risk for progression to malignancy compared with patients with a sole diagnosis of MGUS.
Although mortality may occur because of laryngeal edema, it is more likely due to the complications of the associated disorder.
For patient education information, see the Allergy Center and Hives and Angioedema.
Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972. 1:39-52.
Caballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011. 21(5):333-47; quiz follow 347. [QxMD MEDLINE Link].
Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009 Feb. 15(2):69-78. [QxMD MEDLINE Link].
López-Lera A, Garrido S, Nozal P, Skatum L, Bygum A, Caballero T, et al. Serum complexes between C1INH and C1INH autoantibodies for the diagnosis of acquired angioedema. Clin Exp Immunol. 2019 Dec. 198 (3):341-350. [QxMD MEDLINE Link].
Bidkar VG, Rajan NR, Dasar S, Naik AS, Rao R. Acquired Angioedema: A Rare Manifestation of Angioimmunoblastic T Cell Lymphoma. Indian J Otolaryngol Head Neck Surg. 2019 Oct. 71 (Suppl 1):96-99. [QxMD MEDLINE Link].
Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev. 2008 Dec. 8(2):156-9. [QxMD MEDLINE Link].
Castelli R, Wu MA, Arquati M, Zanichelli A, Suffritti C, Rossi D, et al. High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency. Br J Haematol. 2016 Jan 5. [QxMD MEDLINE Link].
Roy S, Konala VM, Kyaw T, Chakraborty S, Naramala S, Gayam V, et al. An Unusual Case of Acquired Angioedema and Monoclonal Gammopathy of Renal Significance in a Middle-Aged Caucasian Female. J Investig Med High Impact Case Rep. 2020 Jan-Dec. 8:2324709620912096. [QxMD MEDLINE Link].
Banerji A, Sheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc. 2009 Jan-Feb. 30(1):11-6. [QxMD MEDLINE Link].
Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28. 6(1):14. [QxMD MEDLINE Link]. [Full Text].
Bouillet-Claveyrolas L, Ponard D, Drouet C, Massot C. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med. 2003 Oct 1. 115(5):420-1. [QxMD MEDLINE Link].
Engel R, Rensink I, Roem D, Brouwer M, Kalei A, Perry D, et al. ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. J Immunol Methods. 2015 Aug 28. [QxMD MEDLINE Link].
Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol. 2014 Aug. 14 (4):354-62. [QxMD MEDLINE Link].
Zegers IH, Aaldering KN, Nieuwhof CM, Schouten HC. Non-myeloablative allogeneic stem cell transplantation: a new treatment option for acquired angioedema?. Neth J Med. 2015 Oct. 73 (8):383-5. [QxMD MEDLINE Link].
Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019 Mar 13. 14 (1):65. [QxMD MEDLINE Link].
Gobert D, Paule R, Ponard D, Levy P, Frémeaux-Bacchi V, Bouillet L, et al. A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients. Medicine (Baltimore). 2016 Aug. 95 (33):e4363. [QxMD MEDLINE Link].
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med. 2017 Mar 23. 376 (12):1131-1140. [QxMD MEDLINE Link].
Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006 Aug. 119(8):e3-5. [QxMD MEDLINE Link].
Ziakas PD, Giannouli S, Psimenou E, Evangelia K, Tzioufas AG, Voulgarelis M. Acquired angioedema: a new target for rituximab?. Haematologica. 2004 Aug. 89(8):ELT13. [QxMD MEDLINE Link].
Klossowski N, Braun SA, von Gruben V, Losem C, Plewe D, Homey B, et al. [Acquired angioedema with C1-INH deficiency and accompanying chronic spontaneous urticaria in a patient with chronic lymphatic B cell leukemia]. Hautarzt. 2015 Sep 3. [QxMD MEDLINE Link].
Desai HG, Shah SS. Recurrent intestinal obstruction with acquired angio-oedema, due to C1-esterase inhibitor deficiency. J Assoc Physicians India. 2014 Jun. 62 (6):524-5. [QxMD MEDLINE Link].
Kaur R, Williams AA, Swift CB, Caldwell JW. Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema. J Asthma Allergy. 2014. 7:165-7. [QxMD MEDLINE Link].
Dreyfus DH, Na CR, Randolph CC, Kearney D, Price C, Podell D. Successful rituximab B lymphocyte depletion therapy for angioedema due to acquired C1 inhibitor protein deficiency: association with reduced C1 inhibitor protein autoantibody titers. Isr Med Assoc J. 2014 May. 16 (5):315-6. [QxMD MEDLINE Link].
Levi M, Cohn D, Zeerleder S, Dziadzio M, Longhurst H. Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency. Allergy. 2019 Apr. 74 (4):834-840. [QxMD MEDLINE Link].
Rottem M, Mader R. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis. J Rheumatol. 2010 Jan. 37(1):209. [QxMD MEDLINE Link].
Amanda T Moon, MD Clinical Assistant Professor of Dermatology, Children’s Hospital of Philadelphia
Amanda T Moon, MD is a member of the following medical societies: American Academy of Dermatology, Society for Pediatric Dermatology, Women’s Dermatologic Society
Disclosure: Nothing to disclose.
Melody Esmaeili MD Candidate, Perelman School of Medicine at the University of Pennsylvania
Disclosure: Nothing to disclose.
Ru’aa Al Harithy, MBBS, FRCPC Clinical Fellow in Laser and Cosmetic Dermatology, Division of Dermatology, SunnyBrook Hospital, University of Toronto Faculty of Medicine, Canada
Ru’aa Al Harithy, MBBS, FRCPC is a member of the following medical societies: American Academy of Dermatology, Canadian Dermatology Association
Disclosure: Nothing to disclose.
Warren R Heymann, MD Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School
Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology
Disclosure: Nothing to disclose.
William D James, MD Emeritus Professor, Department of Dermatology, University of Pennsylvania School of Medicine
William D James, MD is a member of the following medical societies: American Academy of Dermatology, American Contact Dermatitis Society, Association of Military Dermatologists, Association of Professors of Dermatology, American Dermatological Association, Women’s Dermatologic Society, Medical Dermatology Society, Dermatology Foundation, Society for Investigative Dermatology, Washington DC Dermatological Society, Atlantic Dermatologic Society, Philadelphia Dermatological Society, Pennsylvania Academy of Dermatology, College of Physicians of Philadelphia
Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.
Paul Krusinski, MD Director of Dermatology, Fletcher Allen Health Care; Professor, Department of Internal Medicine, University of Vermont College of Medicine
Paul Krusinski, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.
Kathleen M Rossy, MD Staff Physician, Department of Dermatology, New York Medical College, Metropolitan Hospital
Disclosure: Nothing to disclose.
Robert A Schwartz, MD, MPH Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.
Michael J Wells, MD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.
Source: eMedicine Medscape
This article is provided for informational purposes only and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment.
Leave a Reply